Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for January 2008.

Pharmaceutical Technology
Volume 32, Issue 1

Certifications
FAA Certifies AcuTemp Container


The "RKN" refrigeration container from AcuTemp.
AcuTemp Thermal Systems (Dayton, OH), a leading designer and manufacturer of high-performance insulation and temperature-sensitive packaging, announced that its "RKN" temperature-controlled air-cargo container received Federal Aviation Administration (FAA) approval. FAA granted the approval to AmSafe Bridport (Phoenix, AZ), AcuTemp's partner in the certification process. AcuTemp says the approval marks the first instance that FAA has certified a compressor-driven refrigeration unit, thus permitting its use in the cargo section of an aircraft. The container was designed to allow the air-cargo industry to transport and precisely manage temperatures of perishable items such as vaccines, pharmaceuticals, and reagents.

Vetter Is Certified to Work in Japan

Japan's Ministry for Health, Labor and Welfare gave Vetter Pharma-Fertigung (Ravensburg, Germany) accreditation as a foreign manufacturer for the Japanese pharmaceutical market. Vetter provides aseptic filling of prefilled injection systems. The company was certified in the "drug, sterile product;" "drug, packaging, labeling, and storage;" and "medical device, sterilized medical device" categories.

Expansions
Microfluidics Launches New Website

Microfluidics (Newton, MA) launched its newly redesigned website. The site ( http://www.microfluidicscorp.com/) provides clients an in-depth view of the company and its products using an intuitive navigation system and multimedia content. Visitors can view company news, upcoming events, press releases, newsletters, and industry-specific solutions. The items are organized into categories such as pharmaceutical, biotechnology, and chemical. Visitors also can search for information about topics such as cell disruption, high-shear particle-size reduction, liposomes, emulsions, and carbon nanotubes.

DRAXIS Builds New Facility

DRAXIS Health (Montreal, Canada) began constructing a 77,000-ft2 new secondary-packaging and warehousing facility in St-Anne-de-Bellevue, Quebec. The facility will help DRAXIS produce multiple nonsterile specialty semisolid products for Johnson & Johnson Consumer Companies (Skillman, NJ). The new building is expected to be completed by mid-2008. DRAXIS then will install and validate the facility's equipment and ensure the facility complies with the applicable regulatory requirements.

Advion BioServices Acquires New Instruments

Advion BioServices (Ithaca, NY) the bioanalytical services division of Advion BioSciences, is expanding its capacity with the recent acquisition of two Applied Biosystems–MDS Sciex "API 5000" mass spectrometers and Waters "Acquity" ultraperformance liquid chromatography (UPLC) capability. In addition, the company hired 17 employees after moving to its new laboratory facility in April 2007.

Advion has operated a bioanalytical liquid chromatography–mass spectrometry laboratory since 1993 to serve the pharmaceutical industry. The addition of the new API 5000 mass spectrometers gives Advion's bioanalytical laboratory a total of 24 triple-quadrupole mass spectrometers, thus making it one of the largest bioanalytical contract laboratories in the world. Advion's acquisition of UPLC broadens the range of liquid-chromatography capabilities the company can offer its customers.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here